Further in vitro experiments showed that targeting the SPP1-CD44 axis restored T cell function, and anti-SPP1 treatment significantly reduced tumor burden, either alone or in combination with anti-PD1 therapy in mouse models59. This evidence concerns the gene CD44 and neoplasm.